Amy Taylor
About Amy Taylor
Amy Taylor serves as the Vice President of US Market Access at Insmed Incorporated, bringing over 15 years of experience in operational and pharmaceutical management. She specializes in developing patient support programs and has held various leadership roles across multiple organizations in the industry.
Current Role at Insmed
Amy Taylor currently serves as Vice President of US Market Access at Insmed Incorporated. She has held this position since 2024. In her role, she is responsible for overseeing market access strategies and ensuring that patients have access to Insmed's therapies. Her extensive experience in the pharmaceutical industry supports her leadership in this critical area.
Previous Experience in Pharmaceutical Management
Prior to her current role, Amy Taylor worked at Insmed as Executive Director of Patient Access from 2018 to 2021. She also held the position of Head of US Market Access at Insmed from 2021 to 2024. Her previous roles at Novartis included Associate Director of National Accounts - Specialty Channels and Associate Director of Specialty Services. Amy has over 15 years of experience in operational and pharmaceutical management, focusing on distribution and market access launch strategy.
Education and Expertise
Amy Taylor studied at the University of Wyoming, where she earned a Bachelor of Science degree in Biology and Chemistry from 1989 to 1994. Her educational background provides a strong foundation for her expertise in developing and executing patient support programs, as well as her skills in business development, project management, strategic planning, and business analysis.
Career Path and Consulting Experience
Before joining Insmed, Amy Taylor worked as an Independent Consultant at The Aequitas Group in 2010. She also served as Senior Director at RxCrossroads from 2010 to 2011 and as Senior Program Manager at the same company from 2004 to 2007. Her diverse career includes roles at Celgene as National Account Manager and at Novartis in various capacities, contributing to her comprehensive understanding of the pharmaceutical landscape.